Obesity

Found, the Obesity Medicine Association and the Obesity Action Coalition Take Steps to Close the Gap in Obesity Care With Launch of Obesity Medicine Scholarship

Retrieved on: 
Friday, February 16, 2024

The program will help ensure there are more obesity medicine experts to provide care to those in need by offering resources to medical providers interested in becoming American Board of Obesity Medicine (ABOM) certified.

Key Points: 
  • The program will help ensure there are more obesity medicine experts to provide care to those in need by offering resources to medical providers interested in becoming American Board of Obesity Medicine (ABOM) certified.
  • The Obesity Medicine Scholarship program, funded by Found, encourages physicians to become ABOM certified.
  • The Obesity Medicine Scholarship program aims to bridge the gap by removing the financial barrier of taking the exam.
  • "Without proper training in obesity medicine, it's easy to overlook the inequities that perpetuate the problem," said Kristal Hartman OAC Chair.

“The Weekly Check-Up Podcast” brings acclaimed healthcare talk radio show to larger audience

Retrieved on: 
Thursday, February 15, 2024

“Having produced more than a decade of ‘The Weekly Check-Up’ radio content, it's exciting to introduce a new platform to share the latest healthcare information with as many listeners as possible,” says host Dr. Bruce Feinberg.

Key Points: 
  • “Having produced more than a decade of ‘The Weekly Check-Up’ radio content, it's exciting to introduce a new platform to share the latest healthcare information with as many listeners as possible,” says host Dr. Bruce Feinberg.
  • Since the show began in 2011, Dr. Feinberg has amassed more than 500 hours of content featuring countless thought-provoking questions from listeners.
  • Dr. Feinberg will pair some of the most compelling content from the show’s archives with new, invaluable and practical answers and perspectives.
  • New episodes of “The Weekly Check-Up Podcast” will appear every other week on all major podcast platforms including Spotify, Apple Podcasts, and Google Podcasts.

New Options Medical Weight Loss Clinic Grand Opening in Novi, MI

Retrieved on: 
Thursday, February 15, 2024

DETROIT, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Options Medical Weight Loss™, the nation's premier medical weight loss clinic and provider of medical weight loss solutions, is proud to announce its second clinic in the Metro Detroit area at 26156 Ingersol Dr., Novi, MI 48375. The opening of this clinic, along with twenty-three established locations throughout Florida, Arizona, Ohio, Illinois, Michigan and Indiana represents the company's commitment to reducing the national year-over-year growth of obesity rates through positive life-changing medical weight loss experiences.

Key Points: 
  • Options Medical Weight Loss is the nation's premier medical weight loss clinic offering non-surgical medical weight loss solutions that are safe, effective, and affordable.
  • DETROIT, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Options Medical Weight Loss™, the nation's premier medical weight loss clinic and provider of medical weight loss solutions, is proud to announce its second clinic in the Metro Detroit area at 26156 Ingersol Dr., Novi, MI 48375.
  • The new, state-of-the-art Options Medical Weight Loss Clinic in Novi offers a comprehensive range of services to empower and support patients in achieving their weight loss goals including prescription GLP-1 medications, semaglutide and tirzepatide, one-on-one weight loss coaching, lipotropic fat burning injections, the Options Diet System (ODS) all conveniently accessible to residents in northwest Detroit.
  • At Options Medical Weight Loss, the care team of licensed medical providers and health coaches work together to create customized weight loss plans tailored to patients' individual needs, aspirations, and lifestyles.

Zing Coach acquires interactive workout pioneer Zenia to increase personalization and responsivity within its AI-driven fitness app

Retrieved on: 
Thursday, February 15, 2024

WILMINGTON, Del., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Zing Coach, the Palta-backed healthtech startup reducing growing rates of inactivity and obesity with its AI-powered fitness app, has today announced the acquisition of Zenia, a market leader in real-time workout performance tracking and voice-guided assistance. Zing acquired Zenia's advanced technology, talented team, and proprietary licenses, enabling it to upgrade features such as its realistic AI assistant that puts a health and fitness expert in the pocket of every user.

Key Points: 
  • WILMINGTON, Del., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Zing Coach , the Palta-backed healthtech startup reducing growing rates of inactivity and obesity with its AI-powered fitness app, has today announced the acquisition of Zenia, a market leader in real-time workout performance tracking and voice-guided assistance.
  • Research shows that 38% of the global population is overweight or obese, which significantly raises the risk of life-threatening health conditions.
  • Crucially, the acquisition will enable Zing to improve its powerful AI Assistant, a proactive and responsive fitness coach.
  • Combined with its ongoing research at Zing Lab and continuous development of unique fitness tests based on motion capture and body scanning, the acquisition positions Zing at the forefront of AI-powered fitness solutions.

DoseMe Expands Vancomycin Hemodialysis Model

Retrieved on: 
Thursday, February 15, 2024

DoseMe , a leading provider of model informed precision dosing, today announced the availability of its new Vancomycin Hemodialysis (HD) model.

Key Points: 
  • DoseMe , a leading provider of model informed precision dosing, today announced the availability of its new Vancomycin Hemodialysis (HD) model.
  • The vancomycin hemodialysis (HD) model enables personalized dosing that reduces the necessity for multiple blood draws for vancomycin levels.
  • Implementing this optimized model could further enhance precision and personalization of vancomycin therapy in hemodialysis patients.
  • Overall, integrating the optimized model with DoseMeRx has potential to improve vancomycin dosing accuracy and outcomes in the hemodialysis population.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.

Amwell Executives to Take the Stage at ViVE 2024

Retrieved on: 
Thursday, February 15, 2024

Boston, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in hybrid care enablement, will attend VIVE 2024 , Feb. 25-28, in Los Angeles.

Key Points: 
  • Boston, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in hybrid care enablement, will attend VIVE 2024 , Feb. 25-28, in Los Angeles.
  • In addition, two Amwell executives will lead or participate in ViVE panels:
    Roy Schoenberg, M.D., M.P.H., Amwell president and co-CEO, will moderate the panel: Freaky Friday: Swapping Hospital-Based Care with Virtual Modalities at 9 a.m. PST, Monday, Feb. 26 on the Downtown LA stage.
  • Cynthia Horner, M.D., Amwell chief medical officer, will participate in the panel: From Hospital to Hollywood: The Rise of GLP-1s at 9 a.m. PST, Tuesday, Feb. 27 on the Sunset Strip stage.
  • For more information about Amwell at ViVE or to talk with a company leader during the event, contact [email protected] .

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC).
  • This license agreement marks a pivotal step with PharusDx to develop and commercialize a version of its OncoSweep™ liquid biopsy screening for the early detection of PDAC.
  • The poor survival rate is mainly due to late-stage diagnosis, attributed to the pancreas' deep location within the abdominal cavity.
  • The current challenge of asymptomatic early diagnosis of PDAC is anticipated to be addressed by PharusDx's liquid biopsy miRNA test: OncoSweep™.

ZKR Orthopedics Receives IDE Approval for Clinical Trial

Retrieved on: 
Wednesday, February 14, 2024

SAN FRANCISCO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ZKR Orthopedics, Inc., a clinical stage medical device company, announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) for a multicenter prospective clinical trial.

Key Points: 
  • SAN FRANCISCO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ZKR Orthopedics, Inc., a clinical stage medical device company, announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) for a multicenter prospective clinical trial.
  • We expect the data collected by this trial will establish a strong foundation of compelling clinical evidence for the LIFT implant approval for clinical use," commented David Cash, CEO of ZKR Orthopedics.
  • The IDE approval announcement was made as part of the ZKR Orthopedics activities at the 2024 American Academy of Orthopedic Surgeons annual meeting in San Francisco.
  • In addition to reporting IDE trial approval, the Company participated in the Canaccord Genuity Musculoskeletal Conference earlier this week.

Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support

Retrieved on: 
Tuesday, February 13, 2024

With more than 106 million U.S. adults potentially eligible to take GLP-1s for weight management, Omada aims to optimize the long-term value of these medications.

Key Points: 
  • With more than 106 million U.S. adults potentially eligible to take GLP-1s for weight management, Omada aims to optimize the long-term value of these medications.
  • The high price of the drugs can result in substantial net new costs to health plans.
  • “Providing a proven and scalable behavior change program with our enhanced GLP-1 Care Track can provide the engaging and effective care experience members need.
  • As an experienced MSK provider, Omada is uniquely positioned to fill the biggest gap in GLP-1 care: maintaining weight through targeted exercise and nutrition,” said Omada Health Chief Medical Officer Carolyn Bradner Jasik, MD.